Recursion Pharmaceuticals (RXRX) Options Chain & Prices $6.06 -0.05 (-0.82%) (As of 10/3/2024 ET) Add Compare Share Share Options Chain Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends RXRX Put and Call Options List 1/15/2027 1/16/2026 3/21/2025 1/17/2025 12/20/2024 11/15/2024 10/18/2024 Options Date Put and Call Options Put Options Call Options Options Type All In The Money Out of The Money Moneyness With Volume Without Volume All Volume Strike Price Min Strike Price Max Export to Excel ExpiresStrike PriceClose PricePut/CallVolumeVolume AskVolume BidOpen InterestImplied VolatilityDeltaTrades10/18/2024$5.00$0.036Put1 - - 126(+0)73.46% (-3.49%)-0.082891110/18/2024$6.00$0.306Put6930141539(+36)71.09% (-1.25%)-0.4330451410/18/2024$6.00$0.391Call544111982(+81)71.09% (-1.25%)0.5678121610/18/2024$7.00$1.010Put11 - 1264(+11)74.81% (-0.21%)-0.802487110/18/2024$7.00$0.095Call5704081422237(+232)76.81% (+5.29%)0.20031936End-of-day options data provided by Trade Alert and Intrinio. Related Companies and Tools Related Companies: SWTX Options Data RCUS Options Data SDGR Options Data RLAY Options Data ABCL Options Data EXAI Options Data EBS Options Data ABSI Options Data ITCI Options Data RVMD Options Data Options Chain Tools: Short Interest TrackerShort Interest IncreasesShort Interest DecreasesUnusual Call VolumeUnusual Put Volume This page (NASDAQ:RXRX) was last updated on 10/4/2024 by MarketBeat.com Staff From Our PartnersWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredTrade Alongside Pelosi, Buffett, and MorePeople don't know that you can trade alongside politicians, lawmakers, and top investors like Warren Buffet, B...Bullseye Trades | SponsoredKamala’s Dirty Election Move… RevealedAccording to former advisor to the CIA, the Pentagon and the White House Jim Rickards… Kamala and her puppe...Paradigm Press | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | SponsoredAI Expert Reveals New PickEveryone’s talking about AI right now, but I’ve been talking about it for years. And now I’ve just released...Brownstone Research | Sponsored44-year Wall Street Vet: “Permanent devastation is coming to America”After 44 years on Wall Street, I've seen it all... Black Monday, the Great Recession, the Covid crash. B...InvestorPlace | SponsoredMassive NVIDIA Sell-Off: Are We Headed for a Market Collapse?You may have heard about NVIDIA's CEO dumping shares of his own company. He sold 4.4 million shares this ye...Behind the Markets | SponsoredNext opportunity for crypto millionsAll the Pieces Falling into Place for Crypto… Unlock the Potential of the 2024 Crypto Bull Run!Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Recursion Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Recursion Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
